(Boursier.com) — Mirati Therapeutics soared by 45% last night on Wall Street to more than $62, for a market capitalization of approximately $4.4 billion, on the rumor of interest from the French Sanofi for the San Diego laboratory. Bloomberg indicates that the French pharmaceutical champion would therefore explore a potential acquisition of the cancer treatment designer Mirati. The agency cites sources familiar with the matter who chose not to be identified because the information is private. Bloomberg adds that deliberations are ongoing on the subject and that there is no certainty that an agreement will be reached. Mirati could also attract the interest of other potential buyers, again according to agency sources.
Mirati is rolling out its first product to patients, a drug called Krazati, used as a second-line treatment for a type of lung cancer in which the KRAS gene has mutated, Bloomberg says. The lab received accelerated approval from the Food & Drug Administration for the treatment in December. A divestiture would give Mirati additional resources to help it commercialize the treatment and fund further studies. Since August, Mirati’s CEO and CFO have resigned. Bloomberg News had already reported last year that the group was attracting the interest of large pharmaceutical companies with a view to a potential takeover…
©2023 Boursier.com
Please note, our “Rumors” section aims to echo the information circulating in the trading rooms. These rumors cannot be verified, so they should be considered with caution.